[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335321-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335321-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-detection-of-malignant-and-premalignant-peripheral-nerve-tumors-using-cell-free-dna-fragmentomics","Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics","","Early detection of neurofibromatosis type 1 (NF1)-associated peripheral nerve sheath tumors (PNST) supports clinical decision-making by enabling earlier definitive treatment and potentially reducing fatal outcomes. This study presents a cell-free DNA (cfDNA) fragmentomic workflow that differentiates nonmalignant, premalignant, and malignant PNST in NF1. Using whole-genome sequencing of plasma cfDNA from 101 NF1 patients and 21 healthy controls, fragment size ratios, end motifs, and NMF-derived signatures identify malignant peripheral nerve sheath tumors and distinguish atypical neurofibromas from benign plexiform neurofibromas.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-detection-of-malignant-and-premalignant-peripheral-nerve-tumors-using-cell-free-dna-fragmentomics/335321/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-detection-of-malignant-and-premalignant-peripheral-nerve-tumors-using-cell-free-dna-fragmentomics/335321.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does this study address in NF1 patients?","Question",{"text":63,"@type":64},"It targets early detection of NF1-associated peripheral nerve sheath tumors to support earlier clinical decision-making and treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was cfDNA generated and analyzed in the study?",{"text":68,"@type":64},"cfDNA was isolated from plasma of NF1 patients and healthy controls, followed by whole-genome sequencing and fragmentomic analyses using size ratios, end motifs, and NMF signatures.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the fragmentomic approach improve compared with prior copy-number based methods?",{"text":72,"@type":64},"Previous cfDNA copy-number signatures identified malignant PNST but could not separate benign from premalignant states; fragmentomics differentiated premalignant atypical neurofibromas and aided classification of cases suspicious for malignancy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335321,1790167330,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics  \nR. Taylor Sundby1, Jeffrey J. Szymanski2,3, Alexander C. Pan1, Paul A. Jones4,7, Sana Z. Mahmood1, Olivia H. Reid1, Divya Srihari4, Amy E. Armstrong5,6, Stacey Chamberlain7, Sanita Burgic7,  \nKara Weekley7, Bga Murray1, Sneh Patel1, Faridi Qaium2, Andrea N. Lucas1, Margaret Fagan1, Anne Dufek1, Christian F. Meyer8, Natalie B. Collins9, Christine A. Pratilas10,11, Eva Dombi1, Andrea M. Gross1, AeRang Kim12, John S.A. Chrisinger13, Carina A. Dehner14, Brigitte C. Widemann1, Angela C. Hirbe4,5,6,7, Aadel A. Chaudhuri2,3, and Jack F. Shern1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe a cell-free DNA (cfDNA) fragmentomic approach that distinguishes nonmalignant, premalignant, and malignant forms of PNST in the cancer predisposition syndrome, NF1 .\u003Cbr>Experimental Design: cfDNA was isolated from plasma samples of a novel cohort of 101 patients with NF1 and 21 healthy controls and underwent whole-genome sequencing. We investigated diagnosis-specific signatures of copy-number alterations with in silico size selection as well as fragment profiles. Fragmentomics were analyzed using complementary feature types: bin-wise fragment size ratios, end motifs, and fragment non-negative matrix factorization signatures.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: The novel cohort of patients with NF1 validated that our previous cfDNA copy-number alteration–based approach identifies malignant PNST (MPNST) but cannot distinguish between benign and premalignant states. Fragmentomic methods were able to differentiate premalignant states including atypical neurofibromas (AN) . Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management.\u003Cbr>Conclusions: Novel cfDNA fragmentomic signatures distinguish AN from benign plexiform neurofibromas and MPNST, enabling more precise clinical diagnosis and management. This study pioneers the early detection of malignant and premalignant PNST in NF1 and provides a blueprint for decentralizing noninvasive cancer surveillance in hereditary cancer predisposition syndromes. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nNeurofibromatosis type 1 (NF1) is the most common heritable cancer predisposition syndrome (CPS) worldwide and is characterized by a spectrum of benign, premalignant, and malignant nervesheath tumors. Approximately 50% of patients with NF1 develop benign plexiform neurofibromas (PN; ref. 1), typically present in infancy or early childhood (2), with a subset of PN evolving into  \n1","cbCaiellcNyweqoO","https://ap.wps.com/l/cbCaiellcNyweqoO","pdf",4848430,14,"English","# Introduction\n# Purpose\n# Experimental Design\n# Results\n# Conclusions","[{\"question\":\"What problem does this study address in NF1 patients?\",\"answer\":\"It targets early detection of NF1-associated peripheral nerve sheath tumors to support earlier clinical decision-making and treatment.\"},{\"question\":\"How was cfDNA generated and analyzed in the study?\",\"answer\":\"cfDNA was isolated from plasma of NF1 patients and healthy controls, followed by whole-genome sequencing and fragmentomic analyses using size ratios, end motifs, and NMF signatures.\"},{\"question\":\"What did the fragmentomic approach improve compared with prior copy-number based methods?\",\"answer\":\"Previous cfDNA copy-number signatures identified malignant PNST but could not separate benign from premalignant states; fragmentomics differentiated premalignant atypical neurofibromas and aided classification of cases suspicious for malignancy.\"}]","Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics | PDF",1790010520,35]